louisakewell, Author at European Medical Journal - Page 68 of 153

EMJ

Celyad announces oral presentation on NKR-2 T Cells Manufacturing for a First-in-Human Clinical Trial in AML and Multiple Myeloma

Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell…

EMJ

Otometrics and Maastrict University Drive Greater Understanding of the Paradigm Shift in Vestibular Assessment with New Master Class

Taastrup, Denmark | April 7, 2016 – GN Otometrics, the leading global manufacturer of hearing and balance instrumentation will host a two-day vestibular…

EMJ

Glycotope Appoints Dr. Alfredo Zurlo as Chief Medical Officer

Berlin, Germany, April 29, 2016 – Glycotope GmbH, a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise, today…

EMJ

Neurological Expertise Crucial to Deal with Devastating Zika Consequences

London, 28 April 2016 — “The Zika virus is more and more showing its ugly face, and the international community increasingly realises the dimensions of…

EMJ

MedDay appoints Catherine Moukheibir as Chairman of its Board of Directors

Paris, France, 27 April 2016 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces the appointment of…

EMJ

Celyad Receives Certification for C-Cure® Non-Clinical Data from the European Medicines Agency (EMA)

C-Cure® (C3BS-CQR-1) is a cardiovascular lineage-committed cell therapy product being developed for the treatment of ischemic heart failure

EMJ

Introducing EMJ Urology 4.1

United Kingdom, April 21, 2016: This edition of the EMJ Urology eJournal, as in previous editions, is full of the latest news, reviews, interviews, and…

EMJ

New Congress on Thrombosis and Haemostasis

Amsterdam, The Netherlands: The very first ECTH will be held at the World Forum in The Hague, The Netherlands, from 28 – 30 September 2016.

EMJ

MammaPrint Genetic Test Can Reduce Use of Post-Surgery Chemotherapy among Early-Stage Breast Cancer Patients

NEW ORLEANS — Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological…

EMJ

Norgine Expands Its Partnership with Apharm to Commercialise ZIVEREL® in New European Countries

LONDON, 15 April 2015, 07:00 AM BST: Norgine B.V. announced today that it has expanded its agreement with Apharm s.r.l. to distribute ZIVEREL® in…